Literature DB >> 29902342

New tools for MHC research from machine learning and predictive algorithms to the tumour immunopeptidome.

Daniel M Altmann1.   

Abstract

At a time when immunology seeks to progress ever more rapidly from characterization of a microbial or tumour antigen to the immune correlates that may define protective T-cell immunity, there is a need for robust tools to enable accurate predictions of peptide-major histocompatibility complex (pMHC) and peptide-MHC-T-cell receptor binding. Improvements in the curation of data sets from high throughput pMHC analysis, such as the NIH Immune Epitope Database (IEDB), and the associated developments of predictive tools rooted in machine-learning approaches, are having significant impact. When such approaches are linked to the powerful empirical immunopeptidome data sets from peptide MHC elution and mass spectrometry, there is considerable potential for rapid translation to T-cell therapies and vaccines.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29902342      PMCID: PMC6002226          DOI: 10.1111/imm.12956

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  8 in total

1.  Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium.

Authors: 
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

2.  Improved methods for predicting peptide binding affinity to MHC class II molecules.

Authors:  Kamilla Kjaergaard Jensen; Massimo Andreatta; Paolo Marcatili; Søren Buus; Jason A Greenbaum; Zhen Yan; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Immunology       Date:  2018-02-06       Impact factor: 7.397

Review 3.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

4.  Machine learning reveals a non-canonical mode of peptide binding to MHC class II molecules.

Authors:  Massimo Andreatta; Vanessa I Jurtz; Thomas Kaever; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

Review 5.  Tools to define the melanoma-associated immunopeptidome.

Authors:  Eva Bräunlein; Angela M Krackhardt
Journal:  Immunology       Date:  2017-08-28       Impact factor: 7.397

6.  Predicted MHC peptide binding promiscuity explains MHC class I 'hotspots' of antigen presentation defined by mass spectrometry eluted ligand data.

Authors:  Emma Christine Jappe; Jens Kringelum; Thomas Trolle; Morten Nielsen
Journal:  Immunology       Date:  2018-03-08       Impact factor: 7.397

7.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset.

Authors:  Cecilia S Lindestam Arlehamn; Anna Gerasimova; Federico Mele; Ryan Henderson; Justine Swann; Jason A Greenbaum; Yohan Kim; John Sidney; Eddie A James; Randy Taplitz; Denise M McKinney; William W Kwok; Howard Grey; Federica Sallusto; Bjoern Peters; Alessandro Sette
Journal:  PLoS Pathog       Date:  2013-01-24       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.